-
1
Signal strength of ADE at the drug level ranked by reports.
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
2
Outcomes distribution of drug patients with the top 50 positive signal frequency by 4 methods (ROR PRR IC MGPS).
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
3
Time-to-onset analysis using the Weibull distribution test.
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
4
-
5
Top 50 drugs sorted by frequency of positive signals stratified by reporter – by 4 methods (ROR PRR IC MGPS).
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
6
Gender Difference analysis of the top 50 drugs ranked by frequency by four methods (ROR PRR IC MGPS).
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
7
Top 50 Drugs with positive signals by frequency – by four methods (ROR PRR IC MGPS).
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
8
Two-by-two contingency table for disproportionality analysis.
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
9
The top 50 drugs by frequency of positive signals stratified by sex – by 4 methods (ROR PRR IC MGPS).
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
10
-
11
The top 25 drugs sorted by frequency of positive signals stratified by age – by 4 methods (ROR PRR IC MGPS).
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”
-
12
The principles of disproportionate measurement and the criteria for signal detection.
出版事項 2025その他の著者: “…Yi Ping Pan (22676526)…”